AMAG Pharmaceuticals (AMAG) : Traders are bullish on AMAG Pharmaceuticals (AMAG) as it has outperformed the S&P 500 by a wide margin of 7.3% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 3.97%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 4.41% in the last 1 week, and is up 9.96% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
AMAG Pharmaceuticals (NASDAQ:AMAG): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $27.44 and $27.28 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $27.92. The buying momentum continued till the end and the stock did not give up its gains. It closed at $27.70, notching a gain of 1.69% for the day. The total traded volume was 699,441 . The stock had closed at $27.24 on the previous day.
The stock has recorded a 20-day Moving Average of 6.13% and the 50-Day Moving Average is 14.79%. AMAG Pharmaceuticals, Inc. is up 39.55% in the last 3-month period. Year-to-Date the stock performance stands at -8.25%.
AMAG Pharmaceuticals (AMAG) : The most positive equity analysts on AMAG Pharmaceuticals (AMAG) expects the shares to touch $80, whereas, the least positive believes that the stock will trade at $27 in the short term. The company is covered by 7 Wall Street Brokerage Firms. The average price target for shares are $46.29 with an expected fluctuation of $18.15 from the mean.
AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on maternal health, anemia and cancer supportive care. The Company markets Makena (hydroxyprogesterone caproate injection), Feraheme (ferumoxytol) Injection for Intravenous (IV) use and MuGard Mucoadhesive Oral Wound Rinse. Feraheme is an IV iron replacement therapy for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD). Feraheme is approved for marketing in the United States. Makena is a drug indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. MuGard is indicated for the management of oral mucositis/stomatitis and all types of oral wounds, including aphthous ulcers/canker sores and traumatic ulcers, such as those caused by oral surgery or ill-fitting dentures or braces.